Reversal PotentailPrice action is showing inverse head and shoulder. and starting to form a higher low away from the ATL.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.2332 EUR
−179.93 M EUR
13.17 M EUR
109.47 M
About Fate Therapeutics, Inc.
Sector
Industry
CEO
Bahram Valamehr
Website
Headquarters
San Diego
Founded
2007
ISIN
US31189P1021
FIGI
BBG005CNC5T8
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Related stocks
Big Bounce - FATEGood Morning,
Looking to see where FATE settles today. There was strong momentum yesterday pushing it out of its bearish trend. As always I keep an eye to see where it settles and then will look for my buy.
Enjoy
13R FATEExpecting a 13R move here.
Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biotechnology company specializing in induced pluripotent stem cell (iPSC) technology to develop cellular immunotherapies for cancer and immune disorders. Below are its key fundamentals:
Financial Overview:
Reven
Whats the fate of FATE?Looking at this US stock,it looks like its at rock bottom.
will FATE rally to $3 or more?
NASDAk pick for today FATE therapeutics STOCK at all time lowswe are practically buying the very dipped stock to ensure low risk and high returns
FATE. Have Faith in this stock.FATE. Have Faith in this stock.
Could snap back to previous channel fast.
Big institional value and insider value.
Gap Down/Bad News Event
No earnings report as of late so I tried to find out what the deal is. Looks like an analyst' downgrade on Friday and some other bad news.
Short is over 24%.
Makes you scratch your head and think WOW!
No recommendation/Dust needs to settle and I guess even dirt can get cheaper )o:
FATE | Incoming Rally - Oversold | LONGFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma,
FATEFATE is an interesting company, just developing. There are about 480 thousand in cash, an annual loss of 173 thousand, Has 8 studies in 1 phase. Probably, it will “accumulate” one more year before significant phase studies (3), which corresponds to the negative scenario. And 2 in partnership with Ja
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Fate Therapeutics, Inc. stocks are traded under the ticker F6T.
We've gathered analysts' opinions on Fate Therapeutics, Inc. future price: according to them, F6T price has a max estimate of 6.87 EUR and a min estimate of 1.72 EUR. Watch F6T chart and read a more detailed Fate Therapeutics, Inc. stock forecast: see what analysts think of Fate Therapeutics, Inc. and suggest that you do with its stocks.
Yes, you can track Fate Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Fate Therapeutics, Inc. is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
F6T earnings for the last quarter are −0.25 EUR per share, whereas the estimation was −0.30 EUR resulting in a 17.34% surprise. The estimated earnings for the next quarter are −0.26 EUR per share. See more details about Fate Therapeutics, Inc. earnings.
Fate Therapeutics, Inc. revenue for the last quarter amounts to 1.62 M EUR, despite the estimated figure of 733.67 K EUR. In the next quarter, revenue is expected to reach 1.17 M EUR.
F6T net income for the last quarter is −28.92 M EUR, while the quarter before that showed −34.77 M EUR of net income which accounts for 16.83% change. Track more Fate Therapeutics, Inc. financial stats to get the full picture.
No, F6T doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 5, 2025, the company has 181 employees. See our rating of the largest employees — is Fate Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Fate Therapeutics, Inc. EBITDA is −137.19 M EUR, and current EBITDA margin is −1.30 K%. See more stats in Fate Therapeutics, Inc. financial statements.
Like other stocks, F6T shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Fate Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.